Peter Lange

Director/Board Member at Technical University of Berlin

80 year

Consumer Services

Health Technology

Profile

Peter Lange is currently the Vice Chairman at the Technical University of Berlin and a Member-Supervisory Board at Vakzine Projekt Management GmbH since 2012.
He previously worked as a Lecturer at Eberhard Karls Universität Tübingen in 1994.
Dr. Lange has an undergraduate degree from the University of Gottingen and a doctorate degree from Eberhard Karls Universität Tübingen.

Peter Lange active positions

Companies	Position	Start
Vakzine Projekt Management GmbH Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.	Corporate Officer/Principal	-
Technical University of Berlin	Director/Board Member	2009-11-15

All active positions of Peter Lange

Former positions of Peter Lange

Companies	Position	End
Eberhard Karls Universität Tübingen	Corporate Officer/Principal	1993-12-31

See the detail of Peter Lange's experience

Training of Peter Lange

University of Gottingen	Undergraduate Degree
Eberhard Karls Universität Tübingen	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Peter Lange's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Vakzine Projekt Management GmbH Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.	Health Technology